Visceral Leishmaniasis Treatment, Europe
Supporting Files
Public Domain
-
Dec 2003
Details
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Europe. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.
-
Subjects:
- Dispatch
- Visceral leishmaniasis
- drug treatment
- pentavalent antimony
- amphotericin B
- Europe
- Adolescent
- Adult
- Amphotericin B
- Animals
- Antiprotozoal Agents
- Child
- Drug Combinations
- Drug Therapy
- Humans
- Leishmania infantum
- Leishmaniasis, Visceral
- Meglumine
- Organometallic Compounds
- Phosphatidylcholines
- Phosphatidylglycerols
- Retrospective Studies
-
Source:Emerg Infect Dis. 9(12):1617-1620.
-
Document Type:
-
Volume:9
-
Issue:12
-
Download URL:
-
File Type:
-
Collection(s):
-
Main Document Checksum:urn:sha256:baa3727dbad7356bbf41ee522c267b51b4de2e7dbce2db1a86156f8898b2f0e0
Supporting Files
CDC STACKS serves as an archival repository of CDC-published products including
scientific findings, journal articles, guidelines, recommendations, or other public health information authored or
co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
You May Also Like
COLLECTION
Emerging Infectious Diseases